Diabetes & Metabolism Journal

Original Article

Metabolic Risk/Epidemiology
Risk Factors and Survival Outcomes of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: A Retrospective Cohort Study: Sang-hyeok Go, Yun Kyung Cho, Eun Hee Koh; Diabetes Metab J. 2026;50(1):115-126. Published online July 22, 2025; DOI: https://doi.org/10.4093/dmj.2024.0455

1,876 View
61 Download

Abstract PDF PubReader ePub: Background
Immune checkpoint inhibitors (ICIs) have transformed the treatment of metastatic solid tumors; however, they induce immune-related adverse events, such as ICI-induced type 1 diabetes mellitus (ICI-T1DM), a rare but serious condition requiring lifelong insulin therapy. We aimed to identify the risk factors and survival outcomes associated with ICI-T1DM to optimize screening and mitigate adverse effects.
Methods
This retrospective cohort study analyzed 6,956 patients treated with ICIs at a tertiary care center between January 1, 2017, and February 28, 2023. ICI-T1DM was classified based on the need for persistent insulin therapy post-ICI and a C-peptide level <1.0 ng/mL. Patient demographics, clinical characteristics, treatment details, and survival outcomes were examined.
Results
ICI-T1DM was identified in 32 patients (0.46%) with a median onset time of 41 weeks. Significant risk factors included pre-existing diabetes (hazard ratio [HR], 2.352; 95% confidence interval [CI], 1.140 to 4.854), combination therapy with anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (HR, 3.666; 95% CI, 1.224 to 10.979), prolonged ICI treatment (≥12 weeks; HR, 4.789; 95% CI, 1.806 to 12.701), and thyroid dysfunction (HR, 4.027; 95% CI, 1.847 to 8.779). ICI-T1DM occurrence and thyroid dysfunction were associated with improved survival (HR, 0.224; 95% CI, 0.093 to 0.539; and HR, 0.616; 95% CI, 0.566 to 0.670).
Conclusion
Patients with pre-existing diabetes, combined anti–PD-1/PD-L1 and anti–CTLA-4 therapy, prolonged ICI treatment (≥12 weeks), and thyroid dysfunction are at high risk of developing ICI-T1DM. The observed survival benefits in patients with ICI-T1DM underscore the importance of aggressive glucose monitoring and patient education for early detection and management.

Review

Pathophysiology
Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice: Yun Kyung Cho, Chang Hee Jung; Diabetes Metab J. 2023;47(6):757-766. Published online July 24, 2023; DOI: https://doi.org/10.4093/dmj.2023.0072

16,153 View
741 Download
29 Web of Science
36 Crossref

With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and anti-programmed cell death-1 (PD-1), for the treatment of malignancies, cases of ICI-induced type 1 diabetes mellitus (ICI-T1DM) have been reported globally. This review focuses on the features and pathogenesis of this disease. T1DM is an immune-related adverse event that occurs following the administration of anti-PD-1 or anti-programmed death ligand-1 (PDL1) alone or in combination with anti-CTLA-4. More than half of the reported cases presented as abrupt-onset diabetic ketoacidosis. The primary mechanism of ICI-T1DM is T-cell stimulation, which results from the loss of interaction between PD-1 and PD-L1 in pancreatic islet. The similarities and differences between ICI-T1DM and classical T1DM may provide insights into this disease entity. ICI-T1DM is a rare but often life-threatening medical emergency that healthcare professionals and patients need to be aware of. Early detection of and screening for this disease is imperative. At present, the only known treatment for ICI-T1DM is insulin injection. Further research into the mechanisms and risk factors associated with ICI-T1DM development may contribute to a better understanding of this disease entity and the identification of possible preventive strategies.

Citations

Citations to this article as recorded by

Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies
Robert Wagner, Martin Füchtenbusch, Michael Hummel, Martin Miszon, Andreas Pfützner, Susanne Reger-Tan, Tobias Wiesner
Diabetes Research and Clinical Practice.2026; 231: 113047. CrossRef
Risk Factors and Survival Outcomes of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: A Retrospective Cohort Study
Sang-hyeok Go, Yun Kyung Cho, Eun Hee Koh
Diabetes & Metabolism Journal.2026; 50(1): 115. CrossRef
Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review
Junhui Zhang, Yuping Zhang, Hongmei Li, Fang Deng, Liling Ma, Wenjing Yang, Hong Yang, Huiqing Yu, Bing Chen, Jiongyu Hu
Endocrine Journal.2026; 73(1): 93. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents
Yun Kyung Cho, Chang Hee Jung
Diabetes & Metabolism Journal.2026; 50(1): 1. CrossRef
Fulminant type 1 diabetes mellitus induced by tislelizumab in a patient with lung adenocarcinoma: a case report
Yuanzhen Feng, Xiankang Cheng, Jiao Liu, Jun Qi, Limin Han
Journal of Medical Case Reports.2026;[Epub] CrossRef
Diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome in patients with cancer: A multicentre study
Rabia K. Shahid, Qasem Haider, Sunil Yadav, Duc Le, Shahid Ahmed
Clinical Medicine.2025; 25(1): 100262. CrossRef
Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi
Journal of Diabetes Investigation.2025; 16(2): 334. CrossRef
Management of Immunotherapy-Induced Type 1 Diabetes
Veronica Brady
Critical Care Nursing Clinics of North America.2025; 37(1): 93. CrossRef
Type I Diabetes—A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection
Raluca-Ileana Pătru, Miruna Ghigeanu, Maria-Alexandra Barbu, Andreea Iuliana Ionescu, Antone-Iordache Ionuț-Lucian
Reports.2025; 8(1): 31. CrossRef
Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis
Cha Len Lee, Israt Jahan Riya, Ifrat Jahan Piya, Thiago Pimentel Muniz, Marcus Otho Butler, Samuel David Saibil
Cancers.2025; 17(7): 1080. CrossRef
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors
Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, Enrica Teresa Tanda, Lara Vera, Mara Boschetti, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Federico Gatto
Frontiers in Endocrinology.2025;[Epub] CrossRef
Efficacy and adverse events of immune checkpoint inhibitors: evidence from non-small cell lung cancer and gastric cancer in Korea and Japan
Mc Neil Valencia, Zeeshan Abbas, Seung Won Lee
Precision and Future Medicine.2025; 9(1): 15. CrossRef
Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review
Huijing Dong, Shengfu Li, Yanmei Peng, Xu Zhang, Jiabin Zheng, Chongxiang Xue, Yumin Zheng, Yixuan Yu, Xingyu Lu, Zixin Hu, Huijuan Cui
Oncology Letters.2025; 29(6): 1. CrossRef
Pembrolizumab-Induced Hypothyroidism and Diabetes Mellitus: A Rare Case Presentation Post-Treatment
Jeevan Perera, Shubham Bhanot
Cureus.2025;[Epub] CrossRef
Risk Factors Associated with the Development of Immune-Checkpoint Inhibitor Diabetes Mellitus: An Integrative Review
Vivian Crowder, Veronica Brady
Life.2025; 15(7): 1063. CrossRef
Prenatal pembrolizumab exposure as the potential link among recurrent necrotizing enterocolitis, neonatal diabetes mellitus and exocrine pancreatic insufficiency: a case report
Pasquale Castaldo, Luigi Altimari, Maria Grazia Capretti, Giulio Maltoni, Andrea Scozzarella, Vittoria Paoletti, Luigi Corvaglia, Arianna Aceti
Italian Journal of Pediatrics.2025;[Epub] CrossRef
Development of type 1 diabetes mellitus after nivolumab dose escalation: A case report
Sayaka Mabuchi, Naoko Adachi, Atsushi Nagasawa, Satoshi Nabika
Medicine.2025; 104(29): e43356. CrossRef
Checkpoint Inhibitor-Associated Diabetes Mellitus Following Rapid Pancreatic Metastasis Resolution: Implications for Endocrine Toxicities in Immunotherapy
Sinead Cadogan, Sadhbh Doherty, Deirdre Kelly, Nigel Glynn
AACE Endocrinology and Diabetes.2025; 12(4): 339. CrossRef
Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus in a Patient With Melanoma: A Case Report
Mati Shavit
Cureus.2025;[Epub] CrossRef
Genome-Wide Aggregated Trans Effects Analysis for Circulating Proteins Indicates a Key Role of Immune Checkpoints in Type 1 Diabetes
Xuan Zhou, Andrii Iakovliev, Stuart McGurnaghan, Buddhiprabha Erabadda, Caroline Hayward, Paul M. McKeigue, Athina Spiliopoulou, Helen M. Colhoun
Diabetes.2025; 74(10): 1873. CrossRef
Natural coumarins as anti-diabetic agents: Mechanisms, therapeutic potential, and amelioration of diabetic complications
Shahnaaz Khatoon, Raabia Naaz, Umam Khan, Fayeqa Qayyum, Shakir Ahamad, Mohammad Saquib, Mohd Kamil Hussain
Phytomedicine.2025; 148: 157339. CrossRef
Atezolizumab-Induced Thyroiditis and Immune Checkpoint Inhibitor (ICI)-Type 1 Diabetes Mellitus: Diagnostic and Therapeutic Challenges in ICI-Associated Endocrinopathies
Rafal Al-Rubaye, Sabha Nadeem, Ahmed Abdulkader Zaki Ali Soliman
Cureus.2025;[Epub] CrossRef
Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus
Viviana Elian, Violeta Popovici, Mihnea Ioan Nicolescu, Alexandra Maria Nicolescu, Sorina Maria Aurelian, Emma Adriana Ozon
Current Issues in Molecular Biology.2025; 47(11): 929. CrossRef
Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review
Xipeng Zhou, Peng Jiang, Mingxiang Chen, Jiashun Chen
Medicine.2025; 104(47): e46310. CrossRef
Immune Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus: An Indian Case Series
Medha N Rao, Aditi Chopra, Aditya G Hegde, Adarsh K S, Gunna Sriharsha
Cureus.2025;[Epub] CrossRef
Beyond Tumor Immunity: The Disruption of Endocrine and Infectious Homeostasis by Immune Checkpoint Inhibitors
Ema Schönberger, Luka Švitek, Barbara Grubišić, Tara Cvijić Perić, Romana Marušić, Nika Vlahović Vlašić, Tomislav Kizivat, Silvija Canecki Varžić, Lorna Stemberger Marić, Ines Bilić Ćurčić
International Journal of Molecular Sciences.2025; 26(23): 11619. CrossRef
Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis
Dwaipayan Saha, Preyangsee Dutta, Abhijit Chakraborty
Biology.2025; 14(12): 1731. CrossRef
Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events
晶晶王
Advances in Clinical Medicine.2024; 14(02): 2706. CrossRef
Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review
Gaocheng Wang, Jingjing Wang, Shuilin Dong, Zhanguo Zhang, Wanguang Zhang, Jianping Zhao
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Type 1 diabetes: immune pathology and novel therapeutic approaches
Eleanor M. Ling, Joana R. N. Lemos, Khemraj Hirani, Matthias von Herrath
Diabetology International.2024; 15(4): 761. CrossRef
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A. Paschou
Endocrine.2024; 87(3): 875. CrossRef
Use pembrolizumab may cause acute and severe adverse reactions: a case report and review
Linna Ouyang, Huixing Liu, Zhixiang Tang, Rui Wu, Yujie Zhong, Haibin Chen
International Journal of Surgery Oncology.2024; 9(3): 40. CrossRef
Pembrolizumab-Induced Insulin-Dependent Diabetes Mellitus in a Patient With Triple-Negative Breast Cancer: A Rare Immune-Related Adverse Event
Mirac Burak Tak, Zaid Munir, Ahmet Aydin
Cureus.2024;[Epub] CrossRef
Diabetes and the associated complications: The role of antioxidants in diabetes therapy and care
Lowell Dilworth, Dewayne Stennett, Aldeam Facey, Felix Omoruyi, Shada Mohansingh, Felix O. Omoruyi
Biomedicine & Pharmacotherapy.2024; 181: 117641. CrossRef
Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors
Kelin Meng, Shengling Fu, Yaochen Huang, Wei Chen, Wenbin Zou
Expert Opinion on Drug Safety.2024; : 1. CrossRef
Fulminant Type 1 Diabetes Mellitus Leading to Diabetic Ketoacidosis and Mesenteric Ischemia With Necrosis Following Pembrolizumab Administration: A Case Report
Mayu Ueki, Takeshi Fukuda, Kenta Oue, Takuma Wada, Toshiyuki Sumi
Cureus.2024;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search